Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Campone

Showing results (251-260 of 302) with videos related to

Pageof 31
Sort By:
Genome Medicine|March 16, 2021
Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter studyCéline Callens, Keltouma Driouch, Anaïs Boulai, et al.
The New England Journal of Medicine|March 9, 2022
Overall Survival with Ribociclib plus Letrozole in Advanced Breast CancerGabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, et al.
International Journal of Cancer|May 16, 2019
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME programWilliam Jacot, Pierre-Etienne Heudel, Julien Fraisse, et al.
Cancer Immunology Research|January 12, 2020
Lactic Acidosis Together with GM-CSF and M-CSF Induces Human Macrophages toward an Inflammatory Protumor PhenotypeLéa Paolini, Clément Adam, Céline Beauvillain, et al.
The Lancet. Oncology|September 7, 2015
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trialChristophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE StudySara A Hurvitz, Miguel Martin, Kyung Hae Jung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2013
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastomaTracy T Batchelor, Paul Mulholland, Bart Neyns, et al.
Breast (Edinburgh, Scotland)|February 9, 2021
Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME programLuc Cabel, Matthieu Carton, Barbara Pistilli, et al.
The Lancet. Oncology|August 31, 2020
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trialVéronique Diéras, Hyo S Han, Bella Kaufman, et al.
Breast Cancer Research and Treatment|January 12, 2008
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysesDavid Cameron, Michelle Casey, Michael Press, et al.
Pageof 31

Showing results (251-260 of 302) with videos related to

Sort By:
Pageof 31
Genome Medicine|March 16, 2021
Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter studyCéline Callens, Keltouma Driouch, Anaïs Boulai, et al.
The New England Journal of Medicine|March 9, 2022
Overall Survival with Ribociclib plus Letrozole in Advanced Breast CancerGabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, et al.
International Journal of Cancer|May 16, 2019
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME programWilliam Jacot, Pierre-Etienne Heudel, Julien Fraisse, et al.
Cancer Immunology Research|January 12, 2020
Lactic Acidosis Together with GM-CSF and M-CSF Induces Human Macrophages toward an Inflammatory Protumor PhenotypeLéa Paolini, Clément Adam, Céline Beauvillain, et al.
The Lancet. Oncology|September 7, 2015
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trialChristophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE StudySara A Hurvitz, Miguel Martin, Kyung Hae Jung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2013
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastomaTracy T Batchelor, Paul Mulholland, Bart Neyns, et al.
Breast (Edinburgh, Scotland)|February 9, 2021
Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME programLuc Cabel, Matthieu Carton, Barbara Pistilli, et al.
The Lancet. Oncology|August 31, 2020
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trialVéronique Diéras, Hyo S Han, Bella Kaufman, et al.
Breast Cancer Research and Treatment|January 12, 2008
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysesDavid Cameron, Michelle Casey, Michael Press, et al.
Pageof 31